DE602006019948D1 - Koppelten rezeptors zur behandlung von makuladegeneration - Google Patents

Koppelten rezeptors zur behandlung von makuladegeneration

Info

Publication number
DE602006019948D1
DE602006019948D1 DE602006019948T DE602006019948T DE602006019948D1 DE 602006019948 D1 DE602006019948 D1 DE 602006019948D1 DE 602006019948 T DE602006019948 T DE 602006019948T DE 602006019948 T DE602006019948 T DE 602006019948T DE 602006019948 D1 DE602006019948 D1 DE 602006019948D1
Authority
DE
Germany
Prior art keywords
macular degeneration
coupled receptor
treatment
related macular
antagonist
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE602006019948T
Other languages
English (en)
Inventor
Pascal Deschatelets
Cedric Francois
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Apellis Pharmaceuticals Inc
Original Assignee
Potentia Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Potentia Pharmaceuticals Inc filed Critical Potentia Pharmaceuticals Inc
Publication of DE602006019948D1 publication Critical patent/DE602006019948D1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/005—Enzyme inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/14—Macromolecular materials
    • A61L27/22—Polypeptides or derivatives thereof, e.g. degradation products
    • A61L27/227—Other specific proteins or polypeptides not covered by A61L27/222, A61L27/225 or A61L27/24
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Transplantation (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Ophthalmology & Optometry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Surgical Instruments (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DE602006019948T 2005-03-11 2006-03-13 Koppelten rezeptors zur behandlung von makuladegeneration Active DE602006019948D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US66075205P 2005-03-11 2005-03-11
PCT/US2006/008960 WO2006099330A2 (en) 2005-03-11 2006-03-13 Compositions comprising modulators of g-protein-coupled receptor for treatment of macular degeneration

Publications (1)

Publication Number Publication Date
DE602006019948D1 true DE602006019948D1 (de) 2011-03-17

Family

ID=36992349

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602006019948T Active DE602006019948D1 (de) 2005-03-11 2006-03-13 Koppelten rezeptors zur behandlung von makuladegeneration

Country Status (6)

Country Link
US (1) US20090117171A1 (de)
EP (1) EP1861114B1 (de)
AT (1) ATE497405T1 (de)
AU (1) AU2006223108A1 (de)
DE (1) DE602006019948D1 (de)
WO (1) WO2006099330A2 (de)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8168584B2 (en) 2005-10-08 2012-05-01 Potentia Pharmaceuticals, Inc. Methods of treating age-related macular degeneration by compstatin and analogs thereof
HUE026001T2 (en) 2007-02-05 2016-04-28 Apellis Pharmaceuticals Inc Compstatin analogues for use in the treatment of the inflammatory condition of the respiratory system
WO2010126833A1 (en) * 2009-04-27 2010-11-04 Jerini Ophthalmic Inc. Sustained release formulations of peptidomimetic drugs and uses thereof
WO2011163394A2 (en) 2010-06-22 2011-12-29 Apellis Pharmaceuticals, Inc. Compstatin analogs for treatment of neuropathic pain
EP2468295A1 (de) 2010-12-21 2012-06-27 Affiris AG Impfstoffe basierend auf Komplementprotein C5a Peptide
JP6618682B2 (ja) 2011-06-22 2019-12-11 アペリス・ファーマシューティカルズ・インコーポレイテッドＡｐｅｌｌｉｓ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． 補体阻害剤による慢性障害の治療方法
WO2013082535A2 (en) * 2011-12-02 2013-06-06 Board Of Regents Of The University Of Nebraska Controlled-release peptide compositions and uses thereof
JP6184982B2 (ja) 2012-02-02 2017-08-23 エスバテック − ア ノバルティス カンパニー エルエルシー 点眼用抗体含有徐放性製剤
SI3660033T1 (sl) 2012-11-15 2021-09-30 Apellis Pharmaceuticals, Inc. Analogi kompstatina z dolgotrajnim delovanjem in sorodni sestavki in postopki
WO2014152391A1 (en) 2013-03-15 2014-09-25 Apellis Pharmaceuticals, Inc. Cell-penetrating compstatin analogs and uses thereof
CA3001128A1 (en) 2015-10-07 2017-04-13 Apellis Pharmaceuticals, Inc. Use of long-acting compstatin analog for treating a complement-mediated eye disorder
WO2017127761A1 (en) 2016-01-20 2017-07-27 Vitrisa Therapeutics, Inc. Compositions and methods for inhibiting factor d
WO2018136827A1 (en) 2017-01-20 2018-07-26 Vitrisa Therapeutics, Inc. Stem-loop compositions and methods for inhibiting factor d
KR20190139931A (ko) 2017-04-07 2019-12-18 아펠리스 파마슈티컬스 인코포레이티드 투여 요법 및 관련 조성물 및 방법
WO2021067526A1 (en) 2019-10-02 2021-04-08 Alexion Pharmaceuticals, Inc. Complement inhibitors for treating drug-induced complement-mediated response
WO2021231720A1 (en) 2020-05-15 2021-11-18 Alexion Pharmaceuticals, Inc. Method of using extracellular vesicles to detect complement activation, and uses thereof to assess and/or monitor treatment of a complement-mediated disease

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPO755097A0 (en) * 1997-06-25 1997-07-17 University Of Queensland, The Receptor agonist and antagonist
WO2001084149A2 (en) * 2000-04-29 2001-11-08 University Of Iowa Research Foundation Diagnostics and therapeutics for macular degeneration-related disorders
AUPS160602A0 (en) * 2002-04-08 2002-05-16 University Of Queensland, The Therapeutic method
US7595430B2 (en) * 2002-10-30 2009-09-29 University Of Kentucky Research Foundation Methods and animal model for analyzing age-related macular degeneration

Also Published As

Publication number Publication date
EP1861114B1 (de) 2011-02-02
AU2006223108A1 (en) 2006-09-21
WO2006099330A3 (en) 2007-07-12
US20090117171A1 (en) 2009-05-07
EP1861114A2 (de) 2007-12-05
WO2006099330A2 (en) 2006-09-21
ATE497405T1 (de) 2011-02-15

Similar Documents

Publication Publication Date Title
DE602006019948D1 (de) Koppelten rezeptors zur behandlung von makuladegeneration
MX351152B (es) Compstatina y analogos de la misma para tratar trastornos oculares.
EA201000787A1 (ru) Антигенсвязывающие белки
MA29976B1 (fr) Utilisation d'inhibiteurs de la voie du complement pour traiter des maladies oculaires.
EA200701218A1 (ru) Композиция для лечения ретинол-ассоциированных заболеваний
EA200802135A1 (ru) Фармацевтические композиции антагонистического антитела к cd40
AR066660A1 (es) Prevencion y tratamiento de condiciones del ojo asociadas con su complemento
WO2006015775A3 (en) Egfr kinase inhibitor combinations for treating respiratory and gastrointestinal disorders
EA200800291A1 (ru) Способы и композиции для лечения офтальмологических состояний
EA200900662A1 (ru) Лечение синдрома "сухого глаза" с помощью тестостерона и прогестагена
EA200800337A1 (ru) Композиция и способ введения офтальмологически активных средств
EA200801343A1 (ru) Иммуноглобулины, направленные против nogo
EA200700109A1 (ru) Способы лечения офтальмологических состояний (варианты)
EA200800336A1 (ru) Лечение состояний, связанных с присутствием макромолекулярных агрегатов, в частности глазных расстройств
CY1121865T1 (el) Οφθαλμολογικες συνθεσεις και η χρηση τους
EA200900582A1 (ru) Фармацевтические композиции для профилактики и лечения глазных патологий
WO2019195761A3 (en) Pharmacological agents for treating ocular diseases
WO2006039252A3 (en) Compositions and methods for treating ophthalmic diseases
Bhatta et al. Angiotensin II-induced arterial thickening, fibrosis and stiffening involves elevated arginase function
EA201100462A1 (ru) Серосвязанные соединения для лечения офтальмологических заболеваний и расстройств
ATE495164T1 (de) Thiadiazolderivate zur behandlung neurodegenerativer krankheiten
WO2007096886A3 (en) Composition and methods for treating and preventing age-related macular degeneration
JP2011503094A5 (de)
AR069233A1 (es) Anticuerpos anti- factor b y sus usos
EA200702634A1 (ru) Гуманизированные антитела, специфичные в отношении nogo-a, и их фармацевтические применения